Aidence has also built a deep learning model for this purpose. Aidence’s algorithm successfully predicts lung cancer from a single scan and was awarded in the 2017 Kaggle challenge. Its robust performance was later confirmed in a clinical study comparing its performance to that of 11 radiologists on 300 cases.
Aidence and Google Health intend to complete an AI application for lung nodule malignancy prediction. In this collaboration, Google Health will provide its scientific expertise. Aidence will further develop the model into a solution for clinical practice and bring it to market, complying with relevant data privacy requirements and regulatory standards. The development of this AI application is a statement of intent and no regulatory market applications have been made and no orders for sale are being taken.
Outside of this collaboration with Google Health, Aidence has a proven track record of deploying AI in hospitals and clinics across Europe. Its application, Veye Lung Nodules, is currently running in over 80 routine practice and lung cancer screening sites.
Mark-Jan Harte, Aidence co-founder and CEO, said, “Our mission at Aidence is to give lung cancer patients a fighting chance. This strategic partnership with Google Health allows us to accelerate and expand our efforts toward achieving it.”
Mr. Harte continued, “We are enthusiastic about working on a powerful deep learning model for lung nodule malignancy prediction based on the work of the Aidence and Google teams, as well as making sure that all the other requirements that contribute to the successful deployment of AI in clinical practice are in place, like clinical validation, certification and integration into the clinical workflow.”
Akib Uddin, Product Manager at Google Health, commented, “At Google Health, we want to be an active, catalytic force in demonstrating the real-world benefits of AI in health. We know just how important lung cancer screening is in saving lives, and we are excited to play a role in driving impact at scale by enabling great partners like Aidence with our research.”
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 349 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of approximately 9,000 employees. For more information, visit http://www.radnet.com.